4.6 Review

Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis

Journal

AUTOIMMUNITY REVIEWS
Volume 12, Issue 9, Pages 885-893

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2013.03.011

Keywords

Myasthenia gravis; B cells; Anti-acetylcholine receptor antibodies; Germinal centers; BAFF; Anti-B-cell therapies

Categories

Funding

  1. European Union FIGHT-MG [242210]
  2. Parker Webber Endowed Chair in Neurology (Detroit Medical Center/Wayne State University)
  3. Mary Parker Neuroscience Fund (Detroit Medical Center)
  4. Muscular Dystrophy Association

Ask authors/readers for more resources

Myasthenia gravis (MG) is an autoimmune disease mediated by antibodies directed to molecules of the endplate of the neuromuscular junction. B cells play a major role in MG disease since they produce the pathogenic antibodies and therapies targeting B cells are effective. The aim of this article was to review the role of B cells in myasthenia gravis. We will first describe what we know about B cells in this disease and examine the involvement of the B cells in the thymus of MG patients. We will detail the role of factors associated with B-cell function such as BAFF. Finally, we will discuss the effects of therapy targeting B cells. (C) 2013 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available